Defensive Stock Investment Recommendations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ABT?
Source: Fool
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 107.190
Low
136.00
Averages
148.11
High
169.00
Current: 107.190
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott to Acquire Exact Sciences, Expanding Cancer Screening Market Leadership
- Acquisition Closure: Abbott announced it expects to close the acquisition of Exact Sciences on March 23, 2026, following the receipt of all necessary regulatory approvals, marking a strategic expansion into cancer screening and diagnostics.
- Market Leadership: This acquisition positions Abbott to enter the $60 billion U.S. cancer screening and precision oncology market, with an expected addition of approximately $3 billion in sales in 2026, further strengthening its leadership in the rapidly growing healthcare sector.
- Innovation and Technology Integration: Exact Sciences' leading products, including Cologuard® and Oncotype DX®, will enable Abbott to accelerate the development of cancer detection technologies, enhancing early diagnosis and treatment decision-making for patients, thereby improving health management.
- Financial Impact: While the transaction is expected to dilute 2026 adjusted earnings per share (EPS) by approximately $0.20, Abbott anticipates an acceleration in sales growth of about 0.5%, indicating long-term financial potential and market opportunities.
See More
Defensive Stock Investment Recommendations
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
See More
Defensive Stocks to Strengthen Your Portfolio
- Abbott's Diversification Advantage: Abbott Laboratories operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—allowing it to maintain stable revenue growth during economic fluctuations, with diagnostics revenue surging during the pandemic and now driven by medical devices.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market downturns on their portfolios.
- Intuitive Surgical's Competitive Edge: As the global leader in robotic surgery, Intuitive Surgical's Da Vinci surgical robots command a high price, ensuring hospitals remain loyal to these devices to amortize their investment, thereby creating a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sale of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain financial stability during market downturns and reinforces its leadership position in the healthcare sector.
See More
Health Care Stocks Decline Late Friday
- Overall Decline: Late Friday, the NYSE Health Care Index experienced a downturn, indicating increasing market concerns about the healthcare sector, which may negatively impact investor confidence.
- Market Reaction: The decline in healthcare stocks may be linked to overall economic uncertainty, as investors anticipate potential policy changes that could lead to capital outflows from the sector, thereby affecting stock performance.
- Industry Impact: The weak performance of the healthcare sector could hinder related companies' financing capabilities and market valuations, especially under the current economic conditions where operational pressures are heightened.
- Investor Strategy Adjustment: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors with greater growth potential to mitigate risks associated with market volatility.
See More
Abbott to Acquire Exact Sciences, Enhancing Cancer Screening Leadership
- Acquisition Timeline: Abbott expects to close the acquisition of Exact Sciences on March 23, 2026, following the receipt of all necessary regulatory approvals, marking a strategic expansion into cancer screening and diagnostics.
- Market Growth Potential: This acquisition positions Abbott in the $60 billion U.S. cancer screening and precision oncology market, with an anticipated $3 billion increase in sales in 2026, thereby enhancing the company's growth outlook.
- Enhanced Product Portfolio: Exact Sciences offers leading products like Cologuard® and Oncotype DX®, which aid in early cancer detection and treatment guidance, further solidifying Abbott's leadership in diagnostics.
- Strategic Implications: CEO Robert B. Ford emphasized that this acquisition not only enhances Abbott's growth profile but also drives innovation, expands access to life-changing diagnostics, and helps more individuals detect and manage cancer early.
See More
Abbott's Disappointing Quarter Yet Promising Long-Term Growth
- Weak Revenue Growth: Abbott's fourth-quarter revenue increased by only 4.4% year-over-year to $11.5 billion, primarily dragged down by poor performances in its diagnostic and nutrition segments, resulting in a 22% decline from its 52-week high, which negatively impacts investor confidence.
- Strong Medical Device Performance: Despite overall struggles, Abbott's medical device segment generated $5.7 billion in revenue in Q4, reflecting a 12.3% year-over-year growth, indicating sustained growth potential in this area that could lay the groundwork for future revenue recovery.
- Acquisition Boosts Growth: Abbott's announcement of acquiring Exact Sciences for approximately $21 billion will enhance its diagnostic business, particularly with the Cologuard product addressing over 55 million unscreened patients in the U.S., which is expected to drive revenue growth for the company.
- Dividend Appeal: Following the stock's decline, Abbott's dividend yield exceeds 2.3%, surpassing the S&P 500 average of 1.2%, and with 54 consecutive years of dividend increases, the company demonstrates financial stability and commitment to shareholders.
See More
Abbott to Acquire Exact Sciences, Expanding Cancer Screening Market Leadership
- Acquisition Closure: Abbott announced it expects to close the acquisition of Exact Sciences on March 23, 2026, following the receipt of all necessary regulatory approvals, marking a strategic expansion into cancer screening and diagnostics.
- Market Leadership: This acquisition positions Abbott to enter the $60 billion U.S. cancer screening and precision oncology market, with an expected addition of approximately $3 billion in sales in 2026, further strengthening its leadership in the rapidly growing healthcare sector.
- Innovation and Technology Integration: Exact Sciences' leading products, including Cologuard® and Oncotype DX®, will enable Abbott to accelerate the development of cancer detection technologies, enhancing early diagnosis and treatment decision-making for patients, thereby improving health management.
- Financial Impact: While the transaction is expected to dilute 2026 adjusted earnings per share (EPS) by approximately $0.20, Abbott anticipates an acceleration in sales growth of about 0.5%, indicating long-term financial potential and market opportunities.
See More
Defensive Stock Investment Recommendations
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
See More
Defensive Stocks to Strengthen Your Portfolio
- Abbott's Diversification Advantage: Abbott Laboratories operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—allowing it to maintain stable revenue growth during economic fluctuations, with diagnostics revenue surging during the pandemic and now driven by medical devices.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market downturns on their portfolios.
- Intuitive Surgical's Competitive Edge: As the global leader in robotic surgery, Intuitive Surgical's Da Vinci surgical robots command a high price, ensuring hospitals remain loyal to these devices to amortize their investment, thereby creating a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sale of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain financial stability during market downturns and reinforces its leadership position in the healthcare sector.
See More
Health Care Stocks Decline Late Friday
- Overall Decline: Late Friday, the NYSE Health Care Index experienced a downturn, indicating increasing market concerns about the healthcare sector, which may negatively impact investor confidence.
- Market Reaction: The decline in healthcare stocks may be linked to overall economic uncertainty, as investors anticipate potential policy changes that could lead to capital outflows from the sector, thereby affecting stock performance.
- Industry Impact: The weak performance of the healthcare sector could hinder related companies' financing capabilities and market valuations, especially under the current economic conditions where operational pressures are heightened.
- Investor Strategy Adjustment: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors with greater growth potential to mitigate risks associated with market volatility.
See More
Abbott to Acquire Exact Sciences, Enhancing Cancer Screening Leadership
- Acquisition Timeline: Abbott expects to close the acquisition of Exact Sciences on March 23, 2026, following the receipt of all necessary regulatory approvals, marking a strategic expansion into cancer screening and diagnostics.
- Market Growth Potential: This acquisition positions Abbott in the $60 billion U.S. cancer screening and precision oncology market, with an anticipated $3 billion increase in sales in 2026, thereby enhancing the company's growth outlook.
- Enhanced Product Portfolio: Exact Sciences offers leading products like Cologuard® and Oncotype DX®, which aid in early cancer detection and treatment guidance, further solidifying Abbott's leadership in diagnostics.
- Strategic Implications: CEO Robert B. Ford emphasized that this acquisition not only enhances Abbott's growth profile but also drives innovation, expands access to life-changing diagnostics, and helps more individuals detect and manage cancer early.
See More
Abbott's Disappointing Quarter Yet Promising Long-Term Growth
- Weak Revenue Growth: Abbott's fourth-quarter revenue increased by only 4.4% year-over-year to $11.5 billion, primarily dragged down by poor performances in its diagnostic and nutrition segments, resulting in a 22% decline from its 52-week high, which negatively impacts investor confidence.
- Strong Medical Device Performance: Despite overall struggles, Abbott's medical device segment generated $5.7 billion in revenue in Q4, reflecting a 12.3% year-over-year growth, indicating sustained growth potential in this area that could lay the groundwork for future revenue recovery.
- Acquisition Boosts Growth: Abbott's announcement of acquiring Exact Sciences for approximately $21 billion will enhance its diagnostic business, particularly with the Cologuard product addressing over 55 million unscreened patients in the U.S., which is expected to drive revenue growth for the company.
- Dividend Appeal: Following the stock's decline, Abbott's dividend yield exceeds 2.3%, surpassing the S&P 500 average of 1.2%, and with 54 consecutive years of dividend increases, the company demonstrates financial stability and commitment to shareholders.
See More
